全文获取类型
收费全文 | 35929篇 |
免费 | 3232篇 |
国内免费 | 1033篇 |
专业分类
耳鼻咽喉 | 413篇 |
儿科学 | 472篇 |
妇产科学 | 385篇 |
基础医学 | 2697篇 |
口腔科学 | 815篇 |
临床医学 | 3429篇 |
内科学 | 5387篇 |
皮肤病学 | 550篇 |
神经病学 | 2930篇 |
特种医学 | 2644篇 |
外国民族医学 | 6篇 |
外科学 | 2581篇 |
综合类 | 3352篇 |
现状与发展 | 3篇 |
一般理论 | 1篇 |
预防医学 | 2018篇 |
眼科学 | 2985篇 |
药学 | 6671篇 |
7篇 | |
中国医学 | 1283篇 |
肿瘤学 | 1565篇 |
出版年
2023年 | 703篇 |
2022年 | 865篇 |
2021年 | 1760篇 |
2020年 | 1509篇 |
2019年 | 1387篇 |
2018年 | 1310篇 |
2017年 | 1194篇 |
2016年 | 1194篇 |
2015年 | 1408篇 |
2014年 | 2320篇 |
2013年 | 2386篇 |
2012年 | 2085篇 |
2011年 | 2344篇 |
2010年 | 1781篇 |
2009年 | 1623篇 |
2008年 | 1665篇 |
2007年 | 1721篇 |
2006年 | 1365篇 |
2005年 | 1205篇 |
2004年 | 1031篇 |
2003年 | 891篇 |
2002年 | 733篇 |
2001年 | 647篇 |
2000年 | 590篇 |
1999年 | 515篇 |
1998年 | 444篇 |
1997年 | 457篇 |
1996年 | 371篇 |
1995年 | 397篇 |
1994年 | 388篇 |
1993年 | 334篇 |
1992年 | 278篇 |
1991年 | 277篇 |
1990年 | 270篇 |
1989年 | 260篇 |
1988年 | 208篇 |
1987年 | 216篇 |
1986年 | 203篇 |
1985年 | 259篇 |
1984年 | 236篇 |
1983年 | 180篇 |
1982年 | 228篇 |
1981年 | 158篇 |
1980年 | 149篇 |
1979年 | 118篇 |
1978年 | 87篇 |
1977年 | 95篇 |
1976年 | 78篇 |
1975年 | 65篇 |
1974年 | 51篇 |
排序方式: 共有10000条查询结果,搜索用时 17 毫秒
1.
《Transfusion and apheresis science》2022,61(4):103421
BackgroundTherapeutic plasma exchange (TPE) is an extracorporeal treatment that can be used in adult and pediatric patients with acute demyelinating syndromes of the central nervous system. In this study, the efficacy and safety of TPE was evaluated in 10 pediatric patients who underwent TPE that were unresponsive to corticosteroid treatment.MethodsRecords of 10 pediatric patients who underwent TPE in our pediatric intensive care unit (PICU) between May 2017 and June 2020 were used. Expanded Disability Status Scale (EDSS), Gait Scale (GS), and Visual Outcome Scale (VOS) were applied to the patients before and after TPE.ResultsOf the 10 patients who underwent TPE, five were diagnosed with multiple sclerosis (MS), three with transverse myelitis (TM), and two with acute disseminated encephalomyelitis (ADEM). The median age of the patients was 13.3 years (IQR 8-15), and the median day from symptom onset to onset of TPE was 12.5 days (IQR 7-28). A total of 104 TPE sessions were performed successfully. While no complications were encountered in three patients during the sessions, the most common complication was hypofibrinogenemia. The decrease in EDSS and GS scores was found to be consistent with the clinical response of the patients. There was no statistically significant decrease in the VOS.ConclusionsWith this study, we can say that TPE is a feasible, effective, and safe treatment modality in children with acute demyelinating syndromes of the central nervous system. 相似文献
2.
《European journal of surgical oncology》2022,48(7):1606-1613
BackgroundPseudomyxoma peritonei (PMP) is a rare clinical entity, commonly derived from a mucin-producing tumour of the appendix. International consensus is unclear on the role of positron emission tomography (PET) in preoperative staging. This study aimed to assess the ability of preoperative PET in predicting the histological grade of PMP.MethodsAll patients scheduled for cytoreductive surgery (CRS) +/? hyperthermic intraperitoneal chemotherapy (HIPEC) for PMP who underwent preoperative PET at a single centre between June 2007 and June 2020 were included. A nuclear medicine physician, blinded to patient outcomes, retrospectively reviewed imaging studies to assess for maximum tumour standardised uptake value (SUV) to mean liver SUV ratio (SUVTLR) and maximum porta hepatis SUV to mean liver SUV ratio (SUVPLR).ResultsBetween April 2007 and December 2020, a total of 204 patients underwent surgical intervention for PMP. Of these, 124 (60.8%) met the inclusion criteria. Median peritoneal carcinomatosis index for the entire cohort was 9 and complete cytoreduction (CC0/1) was achieved in 109 (88%) patients. Patients with high-grade PMP were more likely to have diffuse peritoneal disease (p < 0.001) and higher SUVTLR (p<0.001). The area under the ROC curve (AUC) of SUVTLR in predicting high-grade pathology was 71% (p = 0.003). Patients with a SUVTLR ≤ 0.78 had improved disease-free survival (p = 0.042).ConclusionPreoperative PET showed positive correlation with high-grade PMP and acceptable sensitivity and specificity as a diagnostic tool. PET should be considered a useful adjunct to standard imaging for predicting histological grade in the staging of patients with PMP. 相似文献
3.
4.
5.
6.
7.
目的 评价美国国家电器制造协会(National Electrical Manufactures Association, NEMA)最新标准(NU 2-2018)在正电子发射型计算机断层显像/电子计算机断层显像(positron emission tomography/computed tomography, PET/CT)设备性能检测中的作用。 方法 依据最新的NEMA NU 2-2018标准,检测西门子Biograph Vision PET/CT的空间分辨率、灵敏度、散射分数、计数丢失、随机符合、飞行时间分辨率、计数丢失率和随机符合校正精度、图像质量、衰减和散射校正精度及PET与CT配准精度指标。 结果 距视野中心1 cm处横向和轴向空间分辨率分别为3.75 mm和3.76 mm;在视野中心和轴向10 cm处的灵敏度分别为16.83 kcps/MBq和16.67 kcps/MBq;放射性浓度为27.37 kBq/mL时,最大等效噪声计数率为258.26 kcps,散射分数为38.58%;系统时间分辨率为209.82 ps;图像质量模型的对比度恢复系数范围为88.9%~96.2%,背景变异系数范围为2.05%~6.80%,平均肺插件残余误差为2.43%;计数丢失和随机符合校正最大误差为3.9%;距离床板末端 5 cm 和 100 cm处,在距视野中心Y轴1 cm处,PET和CT的配准精度分别为0.46 mm和1.07 mm,在距视野中心X轴20 cm处,PET和CT的配准精度分别为1.06 mm和1.45 mm,在距视野中心Y轴20 cm处PET和CT的配准精度分别为0.85 mm和1.15 mm。 结论 NEMA NU 2-2018标准检测条件更加接近临床,能更好地反映PET/CT设备的系统性能。 相似文献
8.
9.
《Drug discovery today》2022,27(9):2425-2439
Cancer is one of the major causes of mortality, accounting for ~ 9.5 million deaths globally in 2018. The spectrum of conventional treatment for cancer includes surgery, chemotherapy and radiotherapy. Recently, cold plasma therapy surfaced as a novel technique in the treatment of cancer. The FDA approval of the first trial for the use of cold atmospheric plasma (CAP) in cancer therapy in 2019 is evidence of this. This review highlights the mechanisms of action of CAP. Additionally, its applications in anticancer therapy have been reviewed. In summary, this article will introduce the readers to the exciting field of plasma oncology and help them understand the current status and prospects of plasma oncology. 相似文献
10.
Steven P. Rowe MD PhD Martin G. Pomper MD PhD 《CA: a cancer journal for clinicians》2022,72(4):333-352
The authors define molecular imaging, according to the Society of Nuclear Medicine and Molecular Imaging, as the visualization, characterization, and measurement of biological processes at the molecular and cellular levels in humans and other living systems. Although practiced for many years clinically in nuclear medicine, expansion to other imaging modalities began roughly 25 years ago and has accelerated since. That acceleration derives from the continual appearance of new and highly relevant animal models of human disease, increasingly sensitive imaging devices, high-throughput methods to discover and optimize affinity agents to key cellular targets, new ways to manipulate genetic material, and expanded use of cloud computing. Greater interest by scientists in allied fields, such as chemistry, biomedical engineering, and immunology, as well as increased attention by the pharmaceutical industry, have likewise contributed to the boom in activity in recent years. Whereas researchers and clinicians have applied molecular imaging to a variety of physiologic processes and disease states, here, the authors focus on oncology, arguably where it has made its greatest impact. The main purpose of imaging in oncology is early detection to enable interception if not prevention of full-blown disease, such as the appearance of metastases. Because biochemical changes occur before changes in anatomy, molecular imaging—particularly when combined with liquid biopsy for screening purposes—promises especially early localization of disease for optimum management. Here, the authors introduce the ways and indications in which molecular imaging can be undertaken, the tools used and under development, and near-term challenges and opportunities in oncology. 相似文献